-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, A+5qir9Q4Qlv2zb8jI2EuCe21c3qqKGmIpxcHN7tSWzFr7cMAxCsnkjX2+PM88On G+fNGI/dehG0AhD0kjZqFg== 0000950123-02-004095.txt : 20020423 0000950123-02-004095.hdr.sgml : 20020423 ACCESSION NUMBER: 0000950123-02-004095 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20020422 ITEM INFORMATION: Changes in registrant's certifying accountant ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20020423 FILER: COMPANY DATA: COMPANY CONFORMED NAME: POINT THERAPEUTICS INC CENTRAL INDEX KEY: 0000919745 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 043216862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23776 FILM NUMBER: 02618343 BUSINESS ADDRESS: STREET 1: 140 LOCKE DR CITY: MARLBOROUGH STATE: MA ZIP: 01752 BUSINESS PHONE: 5084856850 MAIL ADDRESS: STREET 1: 140 LOCKE DR CITY: MARLOBOROUGH STATE: MA ZIP: 01752 FORMER COMPANY: FORMER CONFORMED NAME: HEMASURE INC DATE OF NAME CHANGE: 19940315 FORMER COMPANY: FORMER CONFORMED NAME: HMSR INC DATE OF NAME CHANGE: 20010618 8-K 1 y59958e8-k.txt POINT THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): APRIL 22, 2002 POINT THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)
DELAWARE 0-19410 04-3216862 (State or other jurisdiction of (Commission file number) (I.R.S. Employer Identification No.) incorporation or organization)
75 KNEELAND STREET 02111 BOSTON, MASSACHUSETTS (Address of principal executive offices) (Zip Code) (617) 636-0680 (Registrant's telephone number, including area code) ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT. On March 15, 2002, Point Therapeutics, Inc. ("Point") (formerly named HMSR Inc.), PT Acquisition Corp., a wholly-owned subsidiary of Point, and Point Therapeutics Massachusetts, Inc. (formerly named Point Therapeutics, Inc.) ("Point Massachusetts") consummated a merger (the "Merger"), pursuant to which PT Acquisition merged with and into Point Massachusetts. Point's business operations after the Merger consist solely of the business previously conducted by Point Massachusetts, which is now a wholly-owned subsidiary of Point. Prior to the Merger, PricewaterhouseCoopers LLP ("PwC") served as Point's (then named HMSR Inc.) independent accountants and Ernst & Young LLP ("E&Y") served as Point Massachusetts' (then named Point Therapeutics, Inc.) independent accountants. On April 22, 2002, the Audit Committee and the Board of Directors of Point dismissed PwC as Point's independent accountants and engaged E&Y to serve as Point's independent accountants. PwC's reports on Point's consolidated financial statements for each of the years ended December 31, 2001 and 2000 did not contain an adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles. During the years ended December 31, 2001 and 2000 and through April 22, 2002, there were no disagreements with PwC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure which, if not resolved to PwC's satisfaction, would have caused it to make reference to the subject matter in connection with its reports on Point's consolidated financial statements for such years; and there were no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K. Point has provided PwC with a copy of the foregoing disclosures. A letter from PwC addressed to the Securities and Exchange Commission is included as Exhibit 16.1 to this Current Report on Form 8-K and states whether PwC agrees with such disclosure. During the years ended December 31, 2001 and 2000 and through the date hereof, Point did not consult Ernst & Young with respect to the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on Point's consolidated financial statements, or any other matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K). ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS. (c) Exhibits .
Exhibit Number Description of Exhibit - ------ ---------------------- 16.1 Letter from PricewaterhouseCoopers LLP to the SEC, dated April 22, 2002, regarding change in certifying accountant.
SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. POINT THERAPEUTICS, INC. /s/ Donald R. Kiepert, Jr. Date: April 23, 2002 By: -------------------------------- Donald R. Kiepert, Jr. President and Chief Executive Officer EXHIBIT INDEX
Exhibit Number Description of Exhibit - ------ ---------------------- 16.1 Letter from PricewaterhouseCoopers LLP to the SEC, dated April 22, 2002, regarding change in certifying accountant.
EX-16.1 3 y59958ex16-1.txt LETTER FROM PRICEWATERHOUSECOOPERS LLP Exhibit 16.1 April 22, 2002 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Commissioners: We have read the statements made by Point Therapeutics, Inc. (formerly HMSR Inc.) (copy attached), which we understand will be filed with the Commission, pursuant to Item 4 of Form 8-K, as part of the Company's Form 8-K report dated April 22, 2002. We agree with the statements concerning our Firm in such Form 8-K. Very truly yours, /s/ PricewaterhouseCoopers LLP PricewaterhouseCoopers LLP -----END PRIVACY-ENHANCED MESSAGE-----